Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $5.4 million.

  • Lifecore Biomedical's Beginning Cash Balance rose 76.28% to $5.4 million in Q2 2025 from the same period last year, while for May 2025 it was $8.5 million, marking a year-over-year decrease of 55.68%. This contributed to the annual value of $8.5 million for FY2025, which is 55.68% down from last year.
  • Latest data reveals that Lifecore Biomedical reported Beginning Cash Balance of $5.4 million as of Q2 2025, which was down 42.71% from $9.5 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Beginning Cash Balance ranged from a high of $10.4 million in Q3 2023 and a low of -$39,000 during Q3 2022.
  • In the last 3 years, Lifecore Biomedical's Beginning Cash Balance had a median value of $5.4 million in 2023 and averaged $5.2 million.
  • In the last 5 years, Lifecore Biomedical's Beginning Cash Balance slumped by 104.96% in 2022 and then skyrocketed by 26,892.31% in 2023.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Beginning Cash Balance stood at $965,000 in 2021, then spiked by 245.08% to $3.3 million in 2022, then soared by 62.79% to $5.4 million in 2023, then grew by 1.83% to $5.5 million in 2024, then spiked by 76.28% to $5.4 million in 2025.
  • Its Beginning Cash Balance stands at $5.4 million for Q2 2025, versus $9.5 million for Q1 2025 and $5.5 million for Q4 2024.